
XOMA (XOMA) Stock Forecast & Price Target
XOMA (XOMA) Analyst Ratings
Bulls say
XOMA Royalty is strategically positioned in the biotechnology space, with a diverse portfolio of early-mid stage clinical assets and a strong track record of acquisitions. Its partnerships with top companies like Moderna and Krystal Biotech demonstrate the potential of its royalty aggregator business model. The recent acquisition of Generation Bio for $35 million in excess cash further strengthens XOMA's financial position. As one of the biotech industry's leading royalty aggregators, XOMA has a promising future ahead with potential monetization of its partnered assets, such as its promising option for ITP patients and potential breakthrough therapy designation for Volixibat. While the recent Phase 3 miss for partner company Rezolute's ersodetug in CHI may have affected its near-term revenue projections, its strong cash balance and continued creativity in transactions make XOMA a strong investment option in the biotech sector.
Bears say
XOMA Royalty is a biotechnology royalty aggregator with a negative outlook as their revenue growth is mainly driven by potential future economics associated with pre-commercial therapeutic candidates and their revenue streams are unpredictable due to the timing of milestone payments. Additionally, despite a strong balance sheet and continued profitability, XOMA's future potential is uncertain due to its recent acquisition by Ligand and a lack of new partnerships. The doubling down on mezagitamab is a positive development, but the undisclosed royalty increase may not significantly impact XOMA's overall revenue. Overall, there are too many uncertainties surrounding XOMA's future, making it a risky investment option.
This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.
XOMA (XOMA) Analyst Forecast & Price Prediction
Start investing in XOMA (XOMA)
Order type
Buy in
Order amount
Est. shares
0 shares